摘要
目的观察和评估玻璃体腔内注射雷珠单克隆抗体(lucentis)治疗视网膜静脉阻塞(RVO)继发黄斑水肿的疗效及安全性。方法前瞻性研究。收集RVO继发黄斑水肿患者45例(45只眼),行玻璃体内注射雷珠单克隆抗体治疗,定期随访,观察术前及术后第1天、半个月、1个月、3个月及6个月的最佳矫正视力、OCT黄斑中心凹视网膜厚度(CMT)、眼底和FFA表现及并发症情况。结果 45例患者平均接受2.98次治疗,术后第1天、半个月、1个月、3个月、6个月平均BCVA分别为0.2257±0.221、0.313±0.274、0.383±0.265、0.463±0.293、0.396±0.260与术前平均视力0.166±0.160比较明显提高(P<0.05,差异具有统计学意义)。术后半个月、1个月、3个月、6个月平均CMT分别为324.232±40.745、278.942±4.933、250.692±5.500、361.712±194.241与术前534.712±131.303比较明显降低(P<0.05,差异具有统计学意义)。眼底观察示治疗后视网膜出血量明显减少,FFA显示视网膜渗漏明显减轻。所有45例眼中,有8例术后出现局部球结膜下出血,3例在术后第1天眼压高于21 mm Hg;所有患者术中及术后未见角膜上皮损伤、无菌性眼炎、感染性眼内炎及视网膜脱离等并发症。结论玻璃体内注射雷珠单克隆抗体治疗RVO继发黄斑水肿安全有效。
Objective To evaluate the efficacy and safety of Ranibizumab intravitreal injection in patients with macular edema secondary to retinal vein occlusion.Methods Forty-five patients （45 eyes） with macular edema seconda-ry to retinal vein occlusion were given intravitreal injections of ranibizumab.During follow-up, the patients＇best-corrected visual acuity （BCVA）, central macular thickness （CMT, measured by using OCT）, fundus findings and other complica-tions were observed at 1 day, 15 days, 1 month, 3 months and 6 months.Results On average, each patient was given ranibizumab intravitreal injection for 2.98 times during the treatment.After treatment, mean post-treatment BCVA were 0.2257 ±0.221, 0.313 ±0.274, 0.383 ±0.265, 0.463 ±0.293, and 0.396 ±0.260 respectively.BCVA measurements significantly improved compared with that before the treatment （0.166 ±0.160;P 〈0.05）.Mean CMT were 324.232 ± 40.745, 278.942 ±4.933, 250.692 ±5.500, and 361.712 ±194.241 from 15 days.These were significantly reduced when compared to baseline CMT 534.712 ±131.303 （P〈0.05）.Fundus imaging showed that hemorrhage absorbed sig-nificantly.FFA showed a significant decrease in retinal leakage.Subconjunctival hemorrhage occurred in 8 patients, and increased intraocular pressure was found in 3 patients on day 1.There were other complications, such as intraoperative and postoperative corneal epithelium damage, aseptic inflammation, infectious endophthalmitis or retinal detachment.Conclu-sion The intravitreal injection of ranibizumab in patients with macular edema secondary to retinal vein occlusion is safe and effective.
出处
《临床眼科杂志》
2015年第4期333-336,共4页
Journal of Clinical Ophthalmology
